KEYTRUDA Now Approved for Patients With PD-L1-Positive Esophageal Squamous Cell Carcinoma Who Have Progressed After Chemotherapy and for a Six-Week Dosing Schedule Across All Adult Indications
https://www.businesswire.com/news/home/20200824005125/en/Merck%E2%80%99s-KEYTRUDA%C2%AE-pembrolizumab-Receives-New-Approvals-Japan